ABL 101
Alternative Names: ABL-101 - ABL Bio; ABL101Latest Information Update: 06 Jul 2023
At a glance
- Originator ABL Bio
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action CD137 antigen agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haematological malignancies
Most Recent Events
- 06 Jul 2023 Preclinical trials in Haematological malignancies in South Korea (Parenteral) (ABL Bio pipeline, July 2023)
- 21 Jun 2022 ABL Bio plans to initiate IND enabling studies forHaematological malignancies in 2023 (Parenteral) (ABL Bio pipeline, June 2022)
- 29 Jun 2021 ABL 101 is available for licensing as of 29 Jun 2021. http://ablbio.com/en/company/main